ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application on a new Diabetes Neuromodulation system utilizing its vagal nerve block ...

At booth #115, Integer will spotlight its latest advancements in neuromodulation and next-generation miniaturized active implantable medical devices (AIMDs). These innovations are designed to ...

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under ...

ReShape Lifesciences® announced the presentation of pre-clinical data for its innovative Diabetes Neuromodulation device at the Minnesota Neuromodulation Symposium. This device employs Hypoglycemia ...

Given the growing interest in non-invasive neuromodulation devices for the central nervous system, the Forum on Neuroscience and Nervous System Disorders hosted a public workshop on March 2-3, 2015 to ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

PLANO, Texas, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, ...

The deal would set up Boston Scientific to compete directly with Medtronic in the market for neuromodulation devices that ...

TAMPA, Fla.--(BUSINESS WIRE)--Neurolief Ltd., a neurotechnology innovator, today announces that it has entered into an exclusive agreement with Sawai Pharmaceutical Co., Ltd. for the development and ...